On Tuesday, UTi Worldwide Inc.(NASDAQ:UTIW)’s shares declined -3.33% to $5.52.
UTi Worldwide Inc. (UTIW), a global supply chain services and solutions provider, has promoted two executives to better align the company’s capabilities and expertise with the evolving needs of its freight forwarding clients.
UTi designated Jerry Trimarco to Global Vice President, Sales — Freight Forwarding. A 40-year veteran of the freight forwarding industry, he joined UTi in 2010 as Vice President, Global Air Product. Formerly, he held senior leadership roles in sales, global transportation, airline administration and field operations with UPS Supply Chain Solutions, Emery Worldwide and Menlo Worldwide.
UTi also designated John Wetherell to Vice President, Global Air Product. A 22-year veteran of the freight forwarding industry, he stated to Trimarco and led UTi’s Air Product and Procurement team in the Americas region. In his new role, he is responsible for the planned development and administration of UTi’s air forwarding business and products globally. He joined UTi in 2006 from Exel, where he began his supply chain career at MSAS, holding senior administration positions in both operations and product administration.
UTi Worldwide Inc. operates as a non-asset-based supply chain services and solutions company. It operates through two segments, Freight Forwarding, and Contract Logistics and Distribution.
BioDelivery Sciences International, Inc.(NASDAQ:BDSI)’s shares dropped -6.95% to $6.96.
BioDelivery Sciences International, Inc. (BDSI) stated that the U.S. Department of Health and Human Services Secretary, Sylvia M. Burwell, declared important new steps to enhance access to treatments for opioid dependence and prevention of opioid overdose. A component of the planned changes comprises a move to expand access to medication assisted treatment (MAT) by revising the regulations that limit the prescribing of buprenorphine to treat opioid dependence.
A recent report from HHS indicated that 2.5 million people in the U.S. presently need treatment for opioid dependence; however, fewer than 1 million are receiving it. Under current regulations, physicians certified can prescribe buprenorphine treatment for opioid dependence for up to 30 patients initially and then after one year can request authorization to prescribe up to a maximum of 100 patients. As a result, access to care is limited and physicians are often forced to turn away patients seeking care.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which comprises of a small, bi-layered erodible polymer film for application to the buccal mucosa.
At the end of Tuesday’s trade, Shire PLC (ADR)(NASDAQ:SHPG)‘s shares dipped -1.72% to $212.01.
Shire (LSE: SHP, NASDAQ: SHPG) recently declared that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. INTUNIV must be used as a part of a comprehensive ADHD treatment program, typically counting psychological, educational and social measures.
The European Commission decision to grant approval is based on data from three pivotal Phase 3 studies investigating the short- and long-term safety and efficacy of INTUNIV in children and adolescents with ADHD.[2]-[4]
The European Commission decision to grant Marketing Authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in July 2015 and applies to all 28 EU member states and Iceland, Liechtenstein and Norway.
Shire plc, a biopharmaceutical company, together with its auxiliaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), counting VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women.
Berry Plastics Group Inc(NYSE:BERY), ended its Tuesday’s trading session with -2.32% loss, and closed at $31.62.
Berry Plastics Group, Inc. (BERY) declared the pricing of the private placement launched September 16, 2015 by one if its indirect, wholly owned auxiliaries (the “Issuer”). The Issuer will issue $400 million of second preceding senior secured notes due 2022 (the “Notes”). The closing of the private placement offering is predictable to occur on or about October 1, 2015.
The Notes will bear interest at a rate of 6.00% payable semiannually, in cash in arrears, on April 15 and October 15 of each year, commencing April 15, 2016 and will mature on October 15, 2022.
Upon the release of proceeds from the collateral account as described below, the Notes will be assumed by Berry Plastics Corporation (“BPC”), a direct and wholly owned partner of Berry Plastics, and will be guaranteed by Berry Plastics and by each of BPC’s existing and future direct or indirect domestic auxiliaries that guarantee BPC’s senior secured, first preceding credit facilities, subject to certain exceptions. The Notes and the guarantees will be senior secured obligations and will rank senior in right of payment to all of BPC’s, and, in the case of the guarantees, to all of the guarantors’, existing and future subordinated debt. The guarantee by Berry Plastics will be unsecured. The Notes and the partner guarantees thereof will be secured on a second-preceding basis, respectively, by liens on the assets of BPC and the partner guarantors that secure BPC’s obligations under its senior secured credit facilities, subject to certain exceptions.
Berry Plastics Group, Inc. manufactures and distributes plastic consumer packaging and engineered materials in North America and internationally. The company operates through four segments: Rigid Open Top, Rigid Closed Top, Engineered Materials, and Flexible Packaging.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
